Small-batch research peptidesThird-party tested for purityDispatched within 24 hoursEvery lot on the recordFree US shipping over $15010% off your first orderFor research use only
Small-batch research peptidesThird-party tested for purityDispatched within 24 hoursEvery lot on the recordFree US shipping over $15010% off your first orderFor research use only
GLP-3
Also known as Retatrutide · LY3437943
Triple GIP / GLP-1 / glucagon agonist — A 39-amino-acid triple agonist targeting GIP, GLP-1 and glucagon receptors, studied for metabolic regulation and body composition in research models.
Purity specification: 99%+Lyophilized powder
Available vial sizes
- 10 mg$109.99In stock
- 20 mg$179.99In stock
From $109.99In stock
View purchase options
Specifications
| CAS number | 2381089-83-2 |
|---|
| Molecular weight | 4731.4 g/mol |
|---|
| Form | Lyophilized powder |
|---|
Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.
Documentation
Certificates of Analysis
Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.
No released lot-specific certificates are currently published for this compound. A certificate appears only after its batch clears release and the source PDF is available.
View the compound COA record →
Research context
Sources and references
What is retatrutide in the published literature?
Retatrutide is described in the literature as an investigational peptide agonist of the GIP, GLP-1, and glucagon receptors. The references below establish research identity and study context; they do not establish the quality, safety, or intended use of any material sold by Astral.
Human phase 2 trial
Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine (2023).
Defines the investigational triple-receptor agonist and its clinical research context; it is not evidence about Astral material.
PMID 37366315 · DOI 10.1056/NEJMoa2301972
Human phase 2a trial
Sanyal AJ, Kaplan LM, Frias JP, et al. Nature Medicine (2024).
Reports a separate clinical research setting for the same investigational molecule; no product-quality inference is made.
PMID 38858523 · DOI 10.1038/s41591-024-03018-2
Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-07-21. How sources are selected.
Read the compound research page →